Related Experiment Video
Updated: Jun 3, 2026
12:24
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma
Bart Burington1, Peng Yue, Xiaoyan Shi
1Department of Biostatistics, Genentech Inc., South San Francisco, CA 94080, USA.
Science Translational Medicine
|March 18, 2011
Summary
CD40 stimulation sensitivity in B cell cancers is linked to p53 mutations and DNA damage. A CD40 gene signature predicts treatment response, aiding in the development of targeted therapies for lymphoma.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- B cells are crucial for adaptive immunity, producing antibodies and undergoing isotype switching.
- CD40 receptor signaling transmits survival signals to B cells, but its role in B cell cancers is complex.
- CD40 stimulation can induce cell death in some B cell cancers, with variable responses observed.
Purpose of the Study:
- To investigate the factors influencing B cell sensitivity to CD40 stimulation in non-Hodgkin's lymphoma.
- To identify biomarkers that predict response to CD40-targeting therapies.
- To explore the relationship between CD40 pathway activation and antitumor activity.
Main Methods:
- Analysis of non-Hodgkin's lymphoma cell lines with varying p53 mutation status.
- Assessment of intrinsic DNA damage, proliferation rates, and BCL6 levels.
- Gene expression analysis to identify a CD40 target gene signature.
- Testing sensitivity to CD40 stimulation with and without DNA-damaging agents.
- Validation in mouse xenograft models and patient data.
Main Results:
- Sensitivity to CD40 stimulation associated with p53 mutation, higher DNA damage, increased proliferation, and elevated BCL6.
- CD40-resistant cell lines showed a pre-existing activated CD40 pathway.
- A gene expression signature of CD40 target genes predicted sensitivity and resistance.
- DNA-damaging agents sensitized resistant cell lines to CD40 stimulation.
- The gene signature predicted tumor shrinkage and progression-free survival in diffuse large B cell lymphoma patients.
Conclusions:
- CD40 pathway activation status is a key determinant of B cell response to CD40 stimulation.
- A predictive gene signature can guide the use of CD40-targeting therapies.
- Understanding CD40 signaling is crucial for developing effective treatments for B cell malignancies.
- This study highlights the potential of dacetuzumab and similar agents in treating diffuse large B cell lymphoma.
Related Concept Videos
01:24B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...